読み込み中
NASDAQHealthcareBiotechnology
最新データ
$13.74
+$0.87 · +6.76%
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
前日終値
$13.74
+$0.87 · +6.76%
時間外
$13.85
+$0.11 · +0.80%
10月9日 19:59 ET
日中の時刻はETです。市場データは遅延する場合があります。
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
日中レンジ
現在 $13.74
52週レンジ
現在 $13.74
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
47
適正価値
センチメント
43
まちまち
リスク
80
高リスク
モメンタム
26
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
日中レンジ
現在 $13.74
52週レンジ
現在 $13.74
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6722.1万 USD | 1.38億 USD | 1.58億 USD | 2.06億 USD | 1235.9万 USD |
| 売上原価 | 302.5万 USD | — | — | — | — |
| 粗利益 | 6419.6万 USD | 1.38億 USD | 1.58億 USD | 2.06億 USD | 1235.9万 USD |
| 研究開発 | 1.12億 USD | 1.95億 USD | 1.92億 USD | 1.48億 USD | 1.74億 USD |
| 販売・一般管理 | 4607.9万 USD | 5282.3万 USD | 5287.1万 USD | 4607.1万 USD | 4145.1万 USD |
| 営業費用 | 1.39億 USD | 2.34億 USD | 2.36億 USD | 1.94億 USD | 2.15億 USD |
| 受取利息 | 1009.5万 USD | 1519.5万 USD | 1735.9万 USD | 258.1万 USD | 75.3万 USD |
| 支払利息 | — | — | 76.7万 USD | 300.1万 USD | 267.4万 USD |
| 減価償却費と償却費 | 302.5万 USD | 354.4万 USD | 295.7万 USD | 152.7万 USD | 119.3万 USD |
| 営業利益 | −7495.5万 USD | −9566.9万 USD | −7820.5万 USD | 1217.7万 USD | −2.03億 USD |
| 純利益 | −6578.3万 USD | −8094.1万 USD | −2972.5万 USD | 934.9万 USD | −2.04億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$30.50
上昇余地（121.98%）この株式へのエクスポージャーを報告している上場投資信託です。
ARK Genomic Revolution ETFARKG3628.35万1.77%15.57億 USD0.75%$51.30+4.08%
Vanguard Morningstar Total Stock Market ETFVTI1176.6万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM915.5万0.01%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF460.73万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Value ETFIWN324.77万0.02%138.48億 USD0.24%$210.87-0.04%
iShares Biotechnology ETFIBB268.56万0.03%102.79億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO227.5万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA175.64万0.01%217.28億 USD0.03%$32.79+0.40%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
